Spread of Nasopharyngeal Carcinoma Is Reduced by Bevacizumab, According to Phase 2 RTOG Trial Results
Friday, December 16, 2011 - 12:31
in Health & Medicine
The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.